Columbia University Medical Center Minority-Based Community Clinical Oncology Pro

描述（由申请人提供）：哥伦比亚大学医学中心赫伯特·欧文综合癌症中心位于纽约曼哈顿北部。在我们的社区，71%是西班牙裔，14%是黑人，31%的居民生活在贫困线以下，癌症是导致多年潜在生命损失的主要原因。因此，我们的挑战是发展科学和服务，在我们的社区预防、控制和治疗癌症。我们的具体目标是：1)吸引和教育潜在的研究参与者，特别是少数民族和缺乏服务的人，参与最先进的癌症临床研究；2)保持参与者参与临床研究并告知研究结果；3)为我们的研究人员（包括当地医学界的研究人员）提供nci赞助的临床合作小组试验和药物研究的菜单，用于筛查、预防、癌症控制和治疗；4)与新组建的NCI临床合作小组建立密切关系，以提高临床研究的效益。在过去的三年里，RRMO和临床试验管理办公室（CRMO）联合招募了超过3,342名受试者进行介入性研究，包括治疗试验、预防和癌症控制研究以及幸存者计划。我们在临床试验中招募了超过2502名少数民族受试者，其中大多数是nci赞助的。尽管RRMO是有效的，但它并不是为所有的研究招募。有了MBCCOP，我们将能够通过以下方式将服务范围扩大到更广泛的参与者：1)支持向更广泛的肿瘤亚专科试验（如儿科、外科专科和更多的肿瘤内科试验）招募外展人员；2)它将允许我们开展更多的癌症控制和预防研究，因为MBCCOP将提供额外的资源。这将使我们能够全面跨越疾病、年龄和治疗范围，扩大器官/部位专业的范围，并在更广泛的癌症研究试验中招募更多的少数族裔患者。

DESCRIPTION (provided by applicant): The Herbert Irving Comprehensive Cancer Center of the Columbia University Medical Center is located in northern Manhattan, New York. In our neighborhood, which is 71% Hispanic and 14% Black, 31% of residents are living below the poverty level, and cancer is the leading cause of years of potential life lost. Our challenge is therefore to develop the science and the services to prevent, control, and treat cancer in our community. Our specific objectives are: 1) to attract and educate potential study participants, especially minorities and the underserved, about participation in state-of-the-art cancer clinical research; 2) to keep participants engaged in their clinical studies and inform them of research results; 3) to provide a menu of NCI-sponsored Clinical Cooperative Group trials and pharmaceutical studies to our investigators, including those in the local medical community, for screening, prevention, cancer control, and treatments; and 4) to establish close relationships with the newly restructured NCI Clinical Cooperative Groups to enhance the benefits of clinical research. In the past three years, the RRMO and the Clinical Trials Management Office (CRMO) have combined to recruit more than 3,342 subjects to interventional studies, including, therapeutic trials, prevention and cancer control studies and survivorship initiatives. We have enrolled more than more than 2,502 minority subjects in clinical trials, most of them NCI-sponsored. Despite the effectiveness of the RRMO, it does not recruit for all studies. With an MBCCOP we will be able to expand the outreach to a broader range of participants by 1) supporting outreach recruitment to a wider range of oncology subspecialty trials, e.g. pediatrics, surgical specialties, and more medical oncology trials, etc. and 2) it will allow us to open more cancer control and prevention studies as there will be additional resources available through the MBCCOP. This will allow us to be comprehensive across the disease, age and treatment spectrum and broaden the range of organ/site specialties and to enroll still more minority patients in a wider range of cancer research trials.